Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000426583 | SCV000517437 | likely pathogenic | not provided | 2021-01-05 | criteria provided, single submitter | clinical testing | Nonsense variant in the C-terminus predicted to result in protein truncation, as the last 41 amino acids are lost, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (Stenson et al., 2014); Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 21841779) |
Labcorp Genetics |
RCV001062791 | SCV001227614 | pathogenic | Combined malonic and methylmalonic acidemia | 2024-07-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp536*) in the ACSF3 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 41 amino acid(s) of the ACSF3 protein. This variant is present in population databases (rs201954387, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with ACSF3-related conditions. ClinVar contains an entry for this variant (Variation ID: 379920). This variant disrupts a region of the ACSF3 protein in which other variant(s) (p.Arg558Trp) have been determined to be pathogenic (PMID: 21841779, 26827111). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV001062791 | SCV002021282 | likely pathogenic | Combined malonic and methylmalonic acidemia | 2021-10-22 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001062791 | SCV002810426 | likely pathogenic | Combined malonic and methylmalonic acidemia | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001062791 | SCV004213862 | likely pathogenic | Combined malonic and methylmalonic acidemia | 2024-03-14 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001062791 | SCV002092438 | likely pathogenic | Combined malonic and methylmalonic acidemia | 2020-10-20 | no assertion criteria provided | clinical testing |